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ABSTRACT 
Histone deacetylases (HDACs) is an enzyme which removes the acetyl group and thus completes 
the reversible modification of histone by acetylation. DNA  in  a chromatin is very tightly 
associated with proteins called histones, which packages in nucleosomes also found in chromatin 
are many nono histones proteins, some of which help maintain chromosomes structures and 
others that regulate the expression of specific genes. Histones are found in all eukaryotic cells 
having molecular weights between 11,000 and 21,000. They are rich in amino acids like arginine 
and lysine. Histones are subjected to enzymatic modification like methylation, acetylation, ADP-
ribosylation, phosphorylation, ubiquitination. Histone acetylation and deacetylation are two 
regulatory and opposing mechanism in leukemia cells. HDACs are major groups for causing 
repression of tumour suppressor genes and hence they cause cancer.  So HDACs can be a  
proved a promising target for curing cancer. 
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                       1. Introduction 
 
Histone acetylation – attachment of acetyl groups (-COCH3) to certain amino acids of histone 
proteins; Histone deacetylation– the removal of acetyl groups (Fig.1). 
 
Fig.1 Mechanism of addition and removal of acetyl group from histones (Yang et al, 2006) 
 
HDACs are multiproteins complexes, like transcriptional corepressors mSin3, N-CoR, and 
SMRT (Glass and Rosenfeld, 2000). This methyl-binding protein complexes recruits HDAC-
containing complexes to methylated gene promoters as a mechanism for gene-transcription 
repression ( Jones et al., 1998) and( Nan et al., 1998).Histone deacetylases (HDAC)  are a new 
class of targeted for cancer , hence inhibition to HDACs mechanism may be proved as  new class  
of inhibitors to cancer they will be used as anticancer agents which are  inducers of growth 
arrest, differentiation, and causes apoptotic cell death of cancer cells vitro and in vivo.. HDAC 
inhibitors are those which selectively altered the expression of genes. They hindered in pathway 
of HDACs mechanism. There are 4 class of HDAC inhibitors-short chain fatty acids (4-
phenylbutyrate and valporicAcid), Hydroxmic acid, (suberoylanilidehydroxamic acid (SAHA), 
pyroxamide, trichostatin A (TSA), cyclic tetra peptides (trapoxin, apicidin). These can induce 
cancer cell death, It has been showed that HDAC inhibitors could be used to induce 
differentiation of leukemia cells or solid tumor cells, for example sodium butyrate and 
trichostatin A (TSA) could increase the remission rate of many kinds of tumors obviously by 
N
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cooperation with other anticancer drugs (4). There by were viewed the progress of histone 
deacetylases inhibitors used in treatment of tumor cells, with analysis of its mechanism. 
Epigenetic regulation of gene transcription is now being been the subject of a fast growing 
research area especially in the field of cancer. Histone deacetylases (HDACs) and histone acetyl 
transferees (HAT) are two families of enzymes that take part in the control of the acetylation 
level of the histone tails rich in amino acids(Marks P et al., 2001;Allfrey VG et al., 1964;de 
Ruijter AJ et al., 2003;Taunton J et al., 1996).HATs transfer acetyl groups to the amino group of 
an lysine residues located in the N-termini of the core histones. It leads to the expansion of 
chromatin and increased accessibility of regulatory proteins to DNA resulting in activation of 
gene transcription. Reversely, HDACs counteract the activity of HATs and remove the acetyl 
groups from lysine residues in histones. This results in chromatin condensation and 
transcriptional repression, this are essential fundamental cellular processes. The main function of  
HDACs are changing chromatin structure and gene transcription, repression of genes required 
for cell proliferation, regulation of gene expression by deacetylation transcription factors, gene 
silencing, differentiation, and participation in cell cycle regulation. In addition, HDACs can also 
acetylate and deacetylated transcription factors and other regulatory protein (Glozak MA et al., 
2005; Fig.2). It has been suggest that deregulation of acetylation and deacetylation plays a 
causative role in the abnormal regulation of gene expression in many forms of cancer (Cress WD 
et al., 2000; Mahlknecht U and Hoelzer D., 2000; Timmermann S et al., 2001). Histone hypo-
acetylation is the overexpression of HDAC and is directly related to the initiation and 
progression of various tumors. In contrast it was seen that histone modification like acetylation, 
deacetylation, methylation and ubiquanation have impact on leukemia cells. E-Cadherin, a 
transmembrane glycoprotein, is also a calcium-dependent cell–cell adhesion molecule, known to 
play a key role in the maintenance of tissue integrity by forming complex with catenin. E-
Cadherin is eventually tagged to actin cytoskeleton through catenins. Because loss of E-cadherin 
expression results in disruption of cellular clusters, it has been postulated that E-cadherin 
functions as tumor suppressor gene. mRNA and protein expression of E-cadherin is frequently 
lost on DNA methylation in multiple cancers at the early stage of tumor progression.(Patra et al, 
2001).HDACs removes the acetyl groups from amino acid rich histone tails and alters the gene 
transcription and leads to the repression of tumour suppresser genes that causes the proliferation 
of cancerous cells. 
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Fig.2 Different ways by which HDACs are recruited to gene promoters. An array of nucleosomes is shown. 
Histone octamers are represented by circles and the DNA is shown in red. Histone deacetylation induced by 
recruitment of HDAC to gene promoters by different factors including, DNA methyl transferases (DNMT), 
the methyl binding protein MeCP2, Estrogen receptor (ER) and transcription factors (E2F, Rb).(Javierre et 
al.,2008) 
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                                      2.   REVIEW  OF LITERATURE  
The transcription process is associated with structural changes in chromatin and the process is 
called chromatin remodeling. This is changes are brought by enzymes that covalently modifies 
the histones of nucleosomes. Acetylation and deacetylation are prominent in this process. 
Histone deacetylases (HDAC) are involved in inducing cancer through their regulation of cell 
proliferation, differentiation. The inhibitors of HDAC exhibit profound effects in cancer 
treatment when combined with their anticancer drugs. The molecular mechanism underlying this 
are not fully understood. The acetylation and deacetylation of lysine in the amino terminal tails 
of core histones play important roles in the remodelling of chromatin and regulation of 
transcription. Histone deacetylases (HDAC) catalyse the removal of acetyl groups from histones 
that cause chromatin condensation and resulting in transcriptional repression. In addition to 
histones, HDACs target many other protein substrates and affect their functions in cell 
proliferation and cell death (Minucci S and Pelicci PG, 2006) and (Bolden JE et al., 2006). 
Mammalian HDACs are categorised into several classes based on their sequence similarity to 
yeast transcription gene.  There are mainly four classes of HDACs- class –I HDACs, class II, 
class III, class –IV. Class IHDACs (HDAC1, HDAC2, HDAC3, and HDAC8) mainly are 
primarily nuclear in localization and expressed and act on multiprotein complexes (Yang XJ and 
Seto E., 2008). Aberrant expression of several class IHDACs in tumor and cancer samples has 
been reported (Halkidou K, et al., 2004)( Wilson AJ et al., 2006)( Zhang Z et al., 2005)( Huang 
BH et al., 2005)( Zhu P,et al., 2004)( Song et al., 2005)( Nakagawa M et al., 2007). The 
relationship between altered expression of HDACs and cancer progression remains largely 
correlative. However, RNA interference (RNAi)–mediated knockdown of individual HDACs, 
these are over expressed in certain tumor cell lines, and suppresses tumor cell growth and 
survival (Wilson AJ et al., 2006) (Huang BH et al., 2005),( Zhu P,et al., 2004 ), (Glaser KB et 
al., 2003), suggesting that over expression of HDACs could contribute to tumor induction and 
progression. In vitro studies have revealed that pharmacologic class I and IIHDAC inhibitors 
(HDACi) can arrest cell growth and induce terminal differentiation and cell death in transformed 
cells.The effect of these is primarily achieved by induction of anti-proliferative, 
prodifferentiative, or proapoptotic genes (Minucci S and Pelicci PG, 2006), (Bolden JE et al., 
2006), (Xu WS et al., 2007). HDACi  can selectively kill cancer cells and have limited toxicity 
for normal cells which is the basic requirement that it should not cause any deleterious effect on 
 Page 5 
 
normal cells. For  this reason several HDACs inhibitor was undergoing clinical trials for their 
anticancer activity. One such inhibitor, suberoylanilidehydroxamic acid (SAHA), it has been 
approved for treatment of cutaneous T-cell lymphoma (Xu WS et al., 2007) and (Marks PA et 
al., 2007).Whereas their activity in preclinical models has been promising, HDAC inhibitors 
have shown relatively good antitumor activity against solid tumors in human clinical trials 
(Nolan L et,. 2008). More recently, their use in combination with other agents has suggested 
greater efficacy( Bolden JE et al., 2006 );that is, HDACi have shown positive or additive effects 
with a wide variety of anticancer reagents, that includes conventional chemotherapeutic drugs 
(Bolden JE et al., 2006 ) and(Xu WS et al., 2007), leading to the suggestion that HDACi lower 
the apoptotic threshold of tumor cells. However, the mechanistic basis of the synergistic effect 
with anticancer agents is not fully understood.HDAC1 is found in multiprotein complexes, such 
as Sin3 (Hassig CA et al., 1997), nucleosome remodelling and deacetylases (Tong JK, et al., 
1998), and corepressors of RE1-silencing transcription factor (Humphrey GW, et al., 2001), 
these two functions as the catalytic subunit. The commonness feature of these complexes is their 
interaction with sequence-specificDNA-binding transcription factors, that repressing 
transcription and cooperating with other chromatin modifiers to shape epigenetic programs 
(Grozinger C and Schreiber SL, 2002). HDAC1-mediated control of epigenetic regulation plays 
vital roles in normal development and tumor progression. For example, in normal development, 
disruption ofHDAC1 causes early embryonic lethality due to increased expression of 
p21( cyclin-dependent kinase inhibitor 1) (Lagger G, et al., 2002). In cancer cells the role of , 
HDAC1 is to repress the expression of tumor suppressive genes such as p21WAF1/CIP1 andBax 
(Lagger G, et al., 2003) and (Juan LJ et al., 2000), leading to aberrant cell proliferation and cell 
viability. Although it has been well shown and recorded that HDAC1 regulates the cell cycle as 
well as the differentiation and death of cells through its interactions with various proteins, less is 
known about the effects of  HDAC1 on cellular sensitivity to stresses such as anticancer drugs, 
chromatin was inactivated by histone deacetylases this inhibit binding of transcription factors 
including RNA polymerase (patra et al,2001) HDACs are not only the cause of cancerous stage 
but over expression of  DNMTs and hypermethylation of –CPG- islands at regulatory regions 
they participate for regulation of transcription in association with biological events including 
cancer development.(patra et al, 2003)  
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2.1 CLASSIFICATION OF HDAC FAMILY MEMBERS  
HDACs are grouped into various classes like, class I, class II, class III and classIV which is 
based on their sequence homology to their yeast orthologuesRpd3, HdaI and Sir2, respectively 
(A.J. de Ruijter et al., 2003) and (I.V. Gregoretti et al., 2004)(Fig.3). Class I, II,and IV are 
referred to as ‘‘classical” HDACs and comprise11 family members , whereas class III members 
are named sirtuins (I.V. Gregoretti et al., 2004). Thier difference is based on their catalytic 
mechanisms. Classical HDACs are metal like Zn2+-dependent enzymes having a catalytic 
pocket in which Zn2+ ion is present at its base that is inhibited by Zn2+ chelating compounds 
such as hydroxamic acids. These compounds are not active against sirtuins as these classIII 
enzymes have a different mechanism of action that requires NAD+ (a cofactor) as an essential 
cofactor (A.J. de Ruijter et al., 2003). The term ‘‘HDAC inhibitors “is commonly used for 
compounds that target the‘‘classical” class I, II, and IV HDACs and that are currently evaluated 
in clinical trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                            Fig.3. Classification of HDACs 
The initially discovered and best studied enzymatic activity of HDACs is the deacetylation of 
histone proteins. Through this mechanism, HDACs control the interaction of positively charged 
HDACS CLASSES 
CLASS-I 
CLASS-II 
CLASS-III 
CLASS-IV 
HDAC-1,-2,-3,-8 
CLASS-IIa 
CLASS-IIb 
SIRT -1, -2, -3, -4, -5, 
-6, -7  
 
HDAC 11  
 
HDAC -4, -5, -7, -9  
 
HDAC -6, -10  
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histones with the negatively charged DNA that is present in form of phosphate group , the 
HDACs inhibits the binding of amino acid with the phosphate group present in the DNA and 
thus regulate chromatin conformation and transcriptional activity. In general, high HDAC 
activity is observed with condensed, transcriptionally inactive chromatin. In surplus to this 
epigenetic function of HDACs, it is recognized that certain HDACs also exhibit important 
cytoplasmic function by controlling the acetylation status and function of numerous cytoplasmic 
proteins and transcription factors. Therefore, the more precise term to be used is for these 
enzymes would be ‘‘lysine deacetylases” as to show that their substrates are not restricted to 
histone proteins (X.J. Yang and  E. Seto ,2008). 
 
2.1.1 CLASS I HDACs 
HDAC family members 1, 2 and 3 are constituent subunits of multiprotein nuclear complexes 
that are important for transcriptional repression and epigenetic functions. For example, HDAC1 
and 2 are components of the HDAC-I complex which are responsible for the expression of 
neuronal genes in non-neuronal tissues (Y. Huang et al., 1999). Complexes containingHDAC1 
and 2 are the NURD and SIN3 repressor complexes (J. Ahringer, 2000). HDAC3 is found within 
the N-COR and SMRT repressor complex (Y.D. Wen et al., 2000). It is to be noted that class I 
member HDAC8 has not been found to be a component of any repressor complex so far, 
itsuggest that a particular function for this class I HDAC.   
 
2.1.2 CLASS II HDACs 
Class II HDAC family members are further sub divided into IIA and IIB. Class IIA members 
HDAC4, 5, 7,9 are generally known by a large, functionally important N-terminal domain that 
regulates nuclear-cytoplasmic shuttling and specific DNA-binding. The nuclear import and 
export signals are regulated by cellular trafficking of these HDACs. They also act as binding site 
for 14-3-3 proteins. HDAC4, 5, 7, 9 has three conserved 14-3-3 binding sites. Cytoplasmic 
retention was induce by binding of the 14-3-3 proteins which in turn regulates the activity of 
transcription factors like the myocyte enhancing  factor-2 (MEF2) (X.J. Yang and  E. Seto 
,2008)( T.A. McKinsey et al 2000)( E. Verdin et al 2000) Major signalling pathways, like 
Ca2+/calmodulin-dependent kinases (CaMKs)( T.A. McKinsey et al 2000), protein kinase-D 
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(R.B. Vega et al 2004), microtubule affinity-regulating kinases (S. Chang et al., 2005), salt-
inducible kinases (R. Berdeaux et al., 2007)and checkpoint kinase-1 (CHK1) (M.A. Kim et al., 
2007) regulate phosphorylation of these 14-3-3 binding sites kinases activity regulates 
phosphorylation of these binding sites. Class IIB HDAC6 has two deacetylase domains and a C-
terminal zinc finger. HDAC6 hasa major cytoplasmic deacetylase functioning as ana-tubulin 
deacetylase(C. Hubbert etal., 2002) and HSP90 deacetylase(J.J. Kovacs et al., 2005) thereby it 
regulates the cell motility, adhesion and chaperone function. , HDAC6 exerts cellular functions 
that are independent from its deacetylase activity. Binding to ubiquitin through its zinc finger 
domain regulates aggresome function, autophagy, heat shock factor-1 (HSF-1) and platelet 
derived growth factor(PDGF) function (Y. Kawaguchi et al., 2003) and ( U.B. Pandey et al., 
2007). HDAC10 is structurally related toHDAC6, but it contains one additional catalytically 
inactive domain that make it differs from HDAC 6 structurally both are same but functions 
different in catalytic way .Its function is largely unknown til now. 
 
2.1.3 CLASS III HDAC 
HDAC-3 is a gene which encodes for enzyme histone deacetylases. It altrs chromosome structure 
and affects transcription factor. Protein encoded by this gene belongs to the histone 
acetylases/deacetylases family. It represses transcription. This protein down regulates p53 
function and hence modulates cell growth and apoptosis. This gene was regarded as potential 
tumor suppressor gene. 
 
2.1.4 CLASS IV HDAC 
Class IV consists of only one that is HDAC11 only. It is structurally related to both, class I and II 
HDACs. Very few information is available about its expression and function. Major number of 
non-histone proteins like those includes, Stat3, HMGs, HSP90, NF-jB,p53, E2Fs, GATA1,Bcl-6 
tubulin, importin, nuclear hormone receptors, and b-catenin are recognized as substrates of 
HDACs (for review see (M. Dokmanovic et al., 2007).For example, HDAC1 has been shown to 
regulate the activity of the transcription factor p53. p53 stability is reduced by deacetylases 
functions it also represses its its transactivation activity and interaction with DNA, and. This in 
turn modulates p53-mediatedcell growth arrest and apoptosis (W. Gu,and R.G. Roeder. 1997) 
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and ( J. Luo et al., 2000). Thus, it can be said that HDACs regulate the activity of cellular key 
players that involves in regulation of transcription, cell cycle, apoptosis, signal transduction and 
others. This clearly shows that HDACs regulate important cellular functions that are independent 
from their epigenetic role in controlling chromatin structure and hence helps in chromatin 
remodelling. 
 
2.2 HDAC FAMILY MEMBERS IN CANCER 
 
HDACs have much function in regulation but, surprisingly little is known about the expression 
of their targets in cancer tissues. A recent study demonstrates resistance to HDAC inhibitors in 
cells lackingHDAC2 expression (S. Ropero et al., 2006). In this section, we review our current 
knowledge on the expression and function of the classical HDAC family members 1–11 in 
cancer cells. HDAC polymorphisms and cancer risk Germline variants of several HDACs have 
been studied leukemia patients. Neither study found evidence for association of HDAC3, 4 and 5 
variants with lung cancer risk (J.M. Park et al., 2005), or HDAC2 and 5 with breast cancer risk 
(A. Cebrian et al.,2006). An insertion of a CAG triplet in the 50-UTR ofHDAC2 was recently 
identified in 18% of 181 cancer samples investigated versus 10% of 192 normal DNA controls(P 
< 0.01) (H. Ozdag et al., 2006). HDAC10 promoter polymorphism in 24 patients with 
hepatocellular carcinoma (HCC) resulted in increased promoter activity in vitro and was 
associated with development of HCC among chronic HBV patients (B.L. Park et al., 2007) 
 
2.3 SOMATIC HDAC MUTATIONS IN CANCER 
 
Somatic mutations of the HDAC2 gene in human epithelial cancers with microsatellite instability 
have been identified in cell lines (S. Ropero et al., 2006) and (H. Ozdag et al., 2006). A HDAC 2 
mutation was detected in 48/228 (21%) of investigated cancers with microsatellite instability in 
which there is loss of HDAC2protein expression (Fig.4). surprisingly, the mutation was viewed 
in  
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Fig.4. A model showing a possible effect of HDAC2 mutation in cancer development. Class I 
HDACs are involved in gene transcription-repression mediated by retinoblastoma protein. The 
loss of HDAC2 function could induce the hyper acetylation and reexpression of genes regulated 
by retinoblastoma protein Rb, and with crucial functions in cell cycle regulation. (Singh et al; 
2010) 
 
functional assays to confer resistance to the anti-proliferative and pro apoptotic effects of HDAC 
inhibitors (S.Ropero et al., 2006).HDAC4 mutations have been identified in breast cancer 
samples at significant frequency in the recent large-scale sequencing study of breast and 
colorectal cancers (T. Sjoblom et al., 2006) 
 
2.4 EXPRESSION AND FUNCTION OF HDACS IN CANCER 
 
HDAC1 expression. In a first study of leukemia cells, HDAC1 expression was up regulated in 
compared with normal tissue (J.H. Choi et al., 2001). Elevated class I HDAC expression was 
significantly associated with nodal spread and it was an independent prognostic marker for 
survival of patients affected with gastric cancer (W. Weichert et al., 2008). In pancreatic cancer, 
it was observed that high HDAC1 expression combined with HIF1were associated with low 
prognosis in a series of 39 pancreatic carcinomas (K. Miyake et al., 2008) Consequently, in a 
larger study involving 192 pancreatic carcinoma samples, high HDAC 1, 2, 3 expressions was 
observed in those which are associated with dedifferentiation and enhanced proliferation of 
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pancreatic cancer cells (W. Weichert et al., 2008). In colorectal cancer, it was observed that  
there was increased HDAC1 expression along with HDAC5, 7 were showed in contrast to breast, 
and bladder cancer(H. Ozdag et al., 2006). In a recent studies of 140 colorectal cancer samples, 
having high HDAC1, 2, 3 expression levels indicates reduced patient survival, with HDAC2 
expression being an independent prognostic factor (W. Weichert et al., 2008). In prostate cancer 
samples, HDAC1 protein expression was observed maximum in hormone refractory, and high 
grade cancer compared with low grade cancer and ultimately with benign prostatic hyperplasia 
(K. Halkidou et al., 2004). In hepatocellular carcinoma, high HDAC1 expression was in 
association with cancer cell invasion into the portal vein, a stage of poorer histological 
differentiation, and a more advanced TNM stage and poor survival of patients in 47 cases (T. 
Rikimaru et al., 2007). In lung cancer, higher HDAC1 expression in advanced stage disease was 
compared with low stage, but no difference was compared with normal lung tissue was reported 
in a series of 102 samples studied (H. Sasaki et al., 2005). In 200 breast cancer samples, HDAC1 
and 3 expression was found to associate with estrogen and progesterone receptor expression and 
HDAC-1 expression was predicted to be  better disease free survival. Multivariate analysis 
demonstrated that HDAC1 was an independent prognostic marker (C.A. Krusche et al., 2005). In 
another studies of 162 breast cancer samples, high HDAC1 expression was associated with better 
survival, negative lymph node status and small tumor size (Z. Zhang et al., 2005). Taken both 
together, these studies show that HDAC1 overexpression appears especially common in cancers 
of the gastrointestinal system and is associated with dedifferentiation of cells, enhanced 
proliferation, invasion, advanced disease and leads poor prognosis. However, these studies 
mostly investigated only HDAC1 and not any other HDAC family member. Essential function of 
HDAC1 in proliferation control and p21 and p27 CDK inhibitor repression has been described 
and shown in mouse embryonic stem cells (K.B. Glaser et al., 2003). In cancer cells, several 
studies have found an important function of HDAC1 in controlling cell proliferation. HDAC1 
and 3 inactivation resulted in inhibition of cell proliferation of HeLa cells, whereas inactivation 
of HDAC4 and 7 did not lead to decreased cell numbers (K.B. Glaser et al., 2003). Knockdown 
of HDAC1 results in arrest either at the G (1) phase of the cell cycle or at the G(2)/M transition, 
that causes loss of mitotic cells and hence leads to activation of oncogenes, leads to cell growth 
inhibition that leads to cancer stage, and an increase in the percentage of apoptotic cells in 
osteosarcoma and breast cancer cells (S. Senese et al., 2007). On the other way, HDAC2 
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knockdown showed no such effects in these cells (S. Senese et al., 2007). Short interval of 
interference of RNA-based inhibition of HDAC1 and HDAC2 suppresses the growth of colon 
cancer cells in vitro (W. Weichert et al., 2008). HDAC1 overexpression leads to an increase in 
proliferation and to an undifferentiated phenotype in cultured prostate cancer cells (K. Halkidou 
et al., 2004). In addition to controlling cell cycle and apoptosis, it has been thought that HDAC1 
might also be associated with multidrug resistance. HDAC1 was overexpressed in chemotherapy 
resistant neuroblastoma cells that was in vitro and siRNA knock down sensitized cells for 
etoposide treatment (N. Keshelava et al., 2007). HDAC1 knockdown by small interference RNA 
stimulated urokinase plasminogen activator expression and invasion of neuroblastoma cells in 
vitro, which was also observed using the unselective HDAC inhibitors TSA, butyrate and 
scriptaid(S.M. Pulukuri et al., 2007)However, recent findings shows that the HDAC inhibitor HC 
toxin efficiently inhibits migration and invasion of MYCN amplified neuroblastoma cells (H.E. 
Deubzer et al., 2008), which could be due to the unique features of this compound compared 
with other HDAC inhibitors investigated in the same culture model (H.E. Deubzer et al., 2008) 
and (H.E. Deubzer et al ., 2008). HDAC1 targeting was recently shown in HeLa cells to induce 
autophagy (M. Oh et al., 2008). Knockdown of HDAC1 and HDAC2 but not HDAC3, HDAC6, 
and HDAC8 was sensitizes CLL cells for TRAIL-induced apoptosis (S. Inoue et al., 2006) 
 
 
 
2.5 MOLECULAR MECHANISM OF HDAC INHIBITORS IN 
ANTICANCER EFFECTS 
 
There are several enzymes, which include acetylates and deacetylases, which can regulate 
transcription by modifying and changing the acetylation state of histones or other promoter-
bound transcription factors. These enzymes reveal their involvement in cell-cycle regulation and 
differentiation. Furthermore, it was suggested that deregulation of acetylase and deacetylases 
activity plays a causative role in the generation of cancer (Kouzarides T., 1999). Restraining 
HDAC activity and preventing the deacetylation of histone may induce hyper acetylation of 
histone that is removal of acetyl moieties, which results in unfolding of ordered chromosome and 
promote transcription factors combined with DNA, so genes which are inhibited can express and 
exert the effect of cure tumor (Brown R and Strathdee G.., 2002) (Fig.5). HDAC enzymes 
remove the acetyl moieties from the histone and give rise to the condition (hypo acetylation), 
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which in turn decrease the space between the nucleosome and the DNA wrapped around it, 
decreasing the transcription factor access and that leads  to transcriptional repression (De Ruijter 
etal.,2003).  
 
                
                Fig.5. Mechanism of HDACs inhibition in flow chart manner (Chiocca, 2010) 
 
Catalytic domain of the HDAC was formed by a stretch of 390 amino acids which contains a set 
of conserved residues. The active site of the enzyme is occupied by a curved tubular pocket with 
a  wide bottom. Removal of an acetyl group occurs through a charge-relay system, an important 
component, to which is the zinc-binding site at the bottom of the pocket. The presence of a zinc 
ion at this site plays an important factor in the mechanism of action of HDAC inhibitors. 
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2.6 EFFECTS OF HDAC INHIBITORS ON SOLID TUMOR CELLS 
In study of HT-29 cells, it was seen that sodium butyrate-mediated growth inhibition is 
associated with a marked decrease in cyclin B1 mRNA levels. These decreased in cyclin B1 
occurred in a delayed fashion (at 24 h), and is completely blocked by concomitant treatment with 
protein synthesis inhibitors, and it appears to be dependent on changes in transcription. Cyclin 
B1 repression is likely to be linked to the differentiation process in colon cancer cells but it is 
observed that it is not relation with growth arrest. The mechanism which required the repression 
of cyclin B1 by butyrate requires prolonged histone hyper acetylation and is at least it is partly 
dependent on p21 expression. In fact, p21/WAF-1 appears to direct repress a minimal cyclin B1 
promoter (-90 bp), a process that can be mediated by the amino-terminal portion of the p21 
protein (Archer SY, et al., 2005). TSA or NaBu blocked two colon cancer cell lines (SW1116 
and Colo-320) mainly in the G1 phase. In these two human colon cancer cell lines, HDAC 
inhibitors increased the p21 (WAF1) gene expression by selectively increasing the degree of 
acetylation of the gene-associated histones, and induced a G1 cell cycle arrest (Chen YX, et al., 
2004). The histone deacetylases inhibitor-induced apoptosis for three pancreatic adenocarcinoma 
cell lines (IMIM-PC-1, IMIM-PC-2 andRWP-1) due to a serine protease-dependent and caspase 
independent mechanism.  Histone deacetylase inhibitors increase Bax protein levels without 
being affecting Bcl-2 levels. Consequently, this induces the apoptosis-inducing factor (AIF) and 
Omi/HtrA2 are released from the mitochondria, with the subsequent starting of the apoptotic 
program. These mechanisms require AIF relocalization into the nuclei that induce DNA 
fragmentation and a serine protease activity of Omi/HtrA2 (Garcia-Morales P et al., 2005). 
Apoptosis of a human lung carcinoma cell line (A549) by TSA was associated with a down-
regulation of anti-apoptotic Bcl-2 protein and an up-regulation of pro-apoptotic Bax protein 
hence Bcl-2 and BAX protein acts opposite to each other one up regulates and other one down 
regulates the pro apoptotic cells. TSA treatment induced the proteolytic activation of caspase-3 
and caspase-9, which results in degradation of poly (ADP-ribose)-polymerase protein. 
Furthermore, it was observed that TSA decreased the levels of COX-2 mRNA and protein 
expression without significant changes at the level of COX-1so TSA brings about the changes in 
COX-2 and not in COX-1, which was correlated with an inhibition in prostaglandin E2 synthesis 
(Choi YH., 2005). Melanoma cells most of the time retain wild-type p53 tumor suppressor 
protein and express it at high levels which suppresses the p-53 pathway of apoptotic mechanism. 
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TSA can stabilize wild-type p53, but due to this p53 protein accumulation was overridden by 
simultaneous down regulation of p53 mRNA leading to a decrease in p53 protein. Growth arrest 
was induced in all cell lines studied and apoptosis in most (6/7), these cellular effects were 
independent of the p53 status of the cells. Dominant negative p53 (175His) inhibits p53 
functions that confirms that the HDAC inhibitor induced apoptosis was independent of wild-type 
p53, even though TSA slightly activated p53. The results shows that p53 does not have any  
action on TSA ,which in turns activates the apoptosis pathway by the HDAC inhibitors that may 
provide therapeutic approaches for melanoma treatment (Peltonen K et al., 2005). Breast cancer 
cell-conditioned medium enhanced phosphorylation of activator transcription factor-2 (ATF-2) 
which was the main modulatory subtype in CREB/ATF-2 family. Inhibition of phosphorylation 
of ATF-2leads to the effect of sodium butyrate on aromatase expression in breast tumor 
fibroblast, and hence, the inhibition of binding of a transcriptional complex containing 
phosphorylated ATF-2, C/EBP β and CREB binding protein (CBP) binds to promoter II and I, 3 
regulatory region. Level of aromatase mRNA arising from cancer-induced promoter region was 
reduced by sodium butyrate. The aberrant activation of promoter II and I,3 in HAF is dependent 
on ATF-2 phosphorylation (Ma D and Zhou JF, 2003). Exposing A2780 ovarian cancer cells to 
the histone deacetylases inhibitor TSA produced a remarkable change in cellular morphology, 
differentiation and proliferation. Within 24 h of TSA treatment, it was observed that there was a 
morphological transformation of the cells, with increased cytoplasm, a more epithelial-like 
columnar appearance, and the rise of distinct cellular boundaries commensurate with the 
morphological transformation, TSA also inhibited cell proliferation. TSA can stimulate 
epithelial-like differentiation with increased cytokeratin expression and the reappearance of 
intercellular plasma membrane junctions and primitive microvillus. In conclusion, it can be 
recorded that the observed TSA-induced changes in p21, Rb, and Id1 have consistent relation 
with cell cycle senescence and differentiation of A2780 ovarian cancer cells (Strait KA, et al., 
2002). 
 
2.7 EFFECTS OF HDAC INHIBITORS ON LEUKEMIA CELLS 
Extensive research of the effect in vitro of many HDAC inhibitor for different tumor cell lines 
showed that HDAC inhibitor can lead many leukemia cell lines to different extent of 
differentiation, apoptosis(cell death) and can block cell circle at G0~G1 period or G2~M period 
 Page 16 
 
hence HDAC regulates the cell cycle and leads to leukemia conditions. The effect depends on the 
type of cell lines, different drugs and action time. Activated fusion proteins such as PML-RARα 
have been shown to inhibit cellular differentiation by recruitment of nuclear co repressor 
complexes, which maintain local HDAC in a variety of hematologic lineage-specific gene 
promoters. HDAC dependent transcriptional repression appears as a common pathway in the 
development of leukemia and could constitute an important target for new therapeutic agents 
(Martinez-Mancilla M et al., 2006). Phenyl butyric acid can induce the differentiation and 
apoptosis of cell lines U937, HL-60, ML-1, K562, NB4, Kasumi-1, et al. Butyric acid and TSA 
can induce NB4 cell line differentiation and apoptosis, and obtain same results of acute 
premyelocytic leukemia patient’s primary cell (Melnick A and  licht JD, 2002) and (Rahmani M, 
et al., 2003). In chronic myelocytic leukemia (CML) the activity of the Bcr-Abl tyrosine kinase 
is known to activate a number of molecular mechanisms, which inhibit apoptosis. SAHA 
induced apoptosis in BV-173 cells, which involves decreased protein expression levels of Bcr-
Abl, c-Myc and HDAC3 (Xu Y,et al., 2005). Depsipeptide can up-regulate IL-3 gene expression 
of AML1/ETO positive leukemia cell, and IL-3 is essential signal transduction regulating gene 
for normal hematopoiesis (Klisovic MI, et al., 2003). Apicidin might induce apoptosis of HL-60 
cell through the help of selective induction of Fas/Fas ligand hence it helps in apoptosis, 
resulting in the release of cytochrome c from the mitochondria to the cytosol and subsequent 
activation of caspase-9 and caspase-3 (Kwon SH, et al., 2002). Low dose of sodium butyrate and 
Trichostatin can induce K562 cell line differentiation. They can block K562 cell cycle in 
different stage, but the differentiation both through inducing P21 and cyclin D3 expresses 
(Shankar S, et al., 2005). HDAC inhibitors enhance the apoptosis-inducing potential of leukemia 
cells lines like (HL60, Jurkat, K562, and U937) through a series of multiple mechanisms, which 
can up-regulate DR4, DR5, Bak, Bax, Bim, Noxa and PUMA, down-regulate IAPs, Mcl-1, Bcl-
2, Bcl-XL and cFLIP, and release mitochondrial proteins like (cytochrome c, Smac/DIABLO 
and Omi/Htr2) to the cytosol, induct p21WAF1/CIP1 and p27KIP1, activate caspase-3 and 
cleave poly (ADP-ribose) polymerase (PARP). The up regulation of death receptors and 
inhibition of cFLIP by HDAC inhibitors will increase the ability of TRAIL to induce apoptosis, 
it is due to enhance activation of caspase-8,and cleavage of Bid, which releases mitochondrial 
proteins to the cytosol, and in turn leads to the activation of caspase-9 and caspase-3 (Shankar S, 
et al., 2005). The link between altered HDAC activity and tumor genesis is probably best 
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demonstrated in acute promyelocytic leukemia (APL). The retinoic acid receptor (RAR) 
transcription factors RARa and its hetero dimerization partner RXR bind to retinoic acid 
response elements (RAREs) and, in the absence of retinoids, repress transcription through a 
complex involving SIN3/HDAC, NCOR and SMRT this complexes helps in repression of 
transcription. Addition of retinoic acid enables HATs (such as TIF2 and CBP) to replace the 
HDACs, thereby activating transcription and ultimately activating tumor repressor genes 
(Altucci L, Gronemeyer H.., 2001) and (Johnstone RW., 2002). HDAC inhibitor can induce 
many lymphocytic leukemia differentiation and apoptosis. Whereas depsipeptide induce bd-6 
positive Raji cell and lymphocytic leukemia cell cycle blockage and apoptosis, chronic 
lymphocytic leukemia cell and myeloma cell are sensitive to HDAC inhibitor either (Rosato RR, 
et al., 2002). SAHA can induce diffuse large cell lymphoma and Hodgkin disease cell lines 
apoptosis. In contrast to that HDAC inhibitors are very sensitive to IL-2 dependent cell lines, 
there have extensive acetylation in these cells, but target genes (like myc) of IL-2 pathway were 
inhibited indicating CD25+（IL-2R）tumor can be treated by HDAC inhibitors (Aron JL etal., 
2003). As been noted above, the anticancer mechanism of HDAC inhibitor is dependent on the 
regulation of gene express, large experiments in vivo and in vitro have confirmed that there are 
three kinds of anticancer mechanisms: 1) block cell cycle and promote cell differentiation, 2) 
induce cell apoptosis, 3) inhibit angiogenesis. 
2.8 PERSPECTIVE 
Anticancer and antagonistic actions of HDAC inhibitors due to inhibition in deacetylation of 
histone mainly thus relieve transcription inhibition of some genes. More genes whose 
transcription activation is related with histone acetylation should be detected following deep 
research of cell proliferation, differentiation and apoptosis, and translation to corresponding 
protein produce further effect. But histone acetylation/ deacetylation as a spot of complex gene 
express regulating net in eukaryotes, is influenced necessarily by other biomolecules. HDAC 
inhibitor has other drug action target except histone: HDAC can induce some hertones as 
transcription factor P53, GATA21, NF2YA deacetylation and regulating activity of binding to 
DNA (Richon VM and O’Brien JP.., 2002). Therefore HDAC inhibitor may selective induce 
some gene expression related with tumor cell differentiation and apoptosis through regulating 
acetylation level of these transcription factors. Careful trial design is important in order to fully 
exploit agents such as the HDAC inhibitors. The use of surrogate markers that does the activity 
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will be important, as a detailed appreciation of their mechanism of action to ensure the optimal 
clinical application in cancer of these agents. The fact that several HDAC inhibitors are in early 
stage clinical trials means we can expect to see an increasing number of published reports on 
their efficacy and potential clinical application. Only understanding common, concrete, key and 
special molecular mechanism of certain kind of tumor invasion, we can choose HDAC inhibitor 
for therapy especially for anticancer drugs. In this way, HDAC inhibitor may become another 
successful inducing differentiation agent for some kinds of tumor after all-trans retinoid acid 
treat acute pre myelocyticleukemia. 
 
 
                                        3. OBJECTIVE 
 
In the light of above text two objectives are decided to fulfill during M.Sc project 
 To compare the RNA isolation from manual method and by kit method 
  To determine the expression profile of histone deacetylases (HDAC) 1 in leukemia cells 
and normal cells 
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4.  MATERIALS AND METHODS 
4.1 COLLECTION OF SAMPLES: 
Blood was collected as the normal tissue from the local CWS Hospital, Rourkela, Odisha, stored in ice 
and immediately processed for better RNA extraction.  Cancer tissue (Lymph Node Carcinoma) was 
collected from National Medical College, Kolkata and stored in 4
o
C until RNA was extracted. 
4.2 EXTRACTION OF TOTAL RNA: 
Total RNA was extracted from blood (normal) and cancer tissue using GeneJET
TM
RNA 
Purification Kit (Fermentas), Manual RNA Extraction techniques and Trizol method. 
4.2.1 EXTRACTION FROM BLOOD BY RNA PURIFICATION KIT:- 
The collected blood was centrifuged at 3000 rpm for 15 mins at 4° C. The supernatant containing 
the serum was separated from the pellet which contains the blood cells. The pellet was re 
suspended in 600 μl of Lysis Buffer (which is supplemented with 20 μl of 14.3, M β-
mercaptoethanol for every 1ml of Lysis Buffer) and that was vortexed so that it will mix 
thoroughly. 450 μl of ethanol (96-100%) was mixed with the solution. About 700 μl of the lysate 
was transferred to a GeneJET
TM
RNA Purification Column inserted in a collection tube and 
centrifuged at 12000 rpm for 1 min at 4° C. The flow-through was discarded and the column was 
placed into a new 2 ml RNase-free micro centrifuge tube. 700 μl of that Wash Buffer 
1(supplemented with 250 μl of ethanol for every 1ml Wash buffer 1) was added to the given 
column and centrifuged for 1 min at 12000 rpm. The flow-through was discarded and 600 μl of 
Wash Buffer 2 (supplemented with 850 μl of ethanol for every 0.5 μl Wash buffer 2) was added 
to the column. It was centrifuged at 12000 rpm for 1 min at 4° C. The flow-through was again 
discarded. Centrifugation was again done at 12000 rpm for 1 min at 4 ° C by adding 250 μl of 
Wash buffer 2. The flow-through was discarded and the column was transferred to a sterile 1.5 
RNase-free microcentrifuge tube which is essential. 100 μl of nuclease-free water was added to 
the column and centrifuged for 1 min at 12000 rpm to elute RNA. The RNA was stored at - 20° 
C for further use or immediately processed for cDNA synthesis. 
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4.2.2. mRNA EXTRACTION FRON BLOOD BY TRIZOL RNA EXTRACTION  
TECHNIQUES:- 
Chemical Reagents and Buffer used during practical-chemical reagents (TRIzol reagents 
(sigma), chloroform, isoproponol, ethanol (70%). Denaturation buffer consists of 50% deionized 
formamides that consists of (2.2 M formaldehyde, MOPS buffer ( P
H 
 -7.0), 6.6% glycerol, 0.5% 
bromophenol, ethidium bromide and agarose. 
 
PROTOCOL- 
50-500 mg of frozen tissue was transferred to a 2ml tube with 1ml TRIzol. It was homogenized 
for 60 sec in the polytron. 200µl of chloroform was added to it. It was mixed by inverting the 
tube for 15 sec then incubated for 3 min at room temperature then it was centrifuged at 12.000g 
for 15 min. aqueous phase was transferred into a fresh Eppi tube. To it added 50µl of 
isopropanol. It was centrifuged at max 7500g for 5 min in the cold room. Pellet was dried on air 
for 10 min it was dissolved in 50-100µl DEPC-H2O and incubated for 10 min at 60
o
c. After that 
spectrophotometer reading was taken. The RNA on a MOPS gel was analysed by the following 
process- 1-3µg RNA was dissolved in 11µl of denaturation buffer, 1µl of ethidium bromide 
(1mg/ml) was added and denatured at 65
o
c for 15 min. it was loaded at 1% agarose gel in MOPS 
buffer plus 5% formaldehyde. Gel was run at 40v for  4 hours 
 
4.2.3. mRNA EXTRACTION BY MANUAL METHOD:- 
Manually mRNA was extracted by using chemical reagents and buffer 
Chemical Reagents and Buffer:-  
a) Chloroform isoamyl alcohol - 49:1 
b) Ethanol 
c) Isopropanol 
d) PBS 
e) Sodium Acetate 
f) Solution D(Denaturating Solutions) 
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              Guanidium Thiocyanate 
             Sodium Citrate 
             Sodium Lawryl Sarcosinate 
             β Mercaptoethanol  
PROCEDURE:- 
             The collected blood sample was centrifuged at 3000rpm for 10 min (room temperature). 
PBS was added and centrifuged (room temperature).The pellet was collected and 2ml of solution 
D was added for 106 cells. The cells were homogenized for 15 to 30 sec in room temperature. 
0.1ml of 2M sodium acetate (pH-4.0), 1ml of phenol and 0.2ml of chloroform: isoamyl alcohol 
per milliliter of solution D was added. It was mixed thoroughly by inversion. The homogenate 
was gently vortexed vigorously for 10 sec; the tube was incubated for 15 minutes on ice to 
permit complete dissociation of nucleoprotein complex. The tube was centrifuged at 9000rpm for 
20 min at 4
◦
C. The extracted RNA was collected in the upper aqueous solution. An equal volume 
of isopropanol was added to the extracted RNA and the solution was mixed and the RNA was 
allowed to precipitate for 1min at -20
◦
C. RNA was collected by centrifugation at 9000rpm at 4
◦
C 
for 30 min. Isopropanol was carefully decanted and the RNA pellet was dissolved in 0.3ml 
Solution D for every 1ml of solution used in early step. The solution was transferred to a 
microfuge tube, it was vortexed well and the RNA was precipitated with 1 volume of 
isopropanol for1 hour or more at -20
◦
C. The precipitate RNA was collected by centrifuge at 
maximum speed for 10mins at 4
◦
C.The pellet was washed twice with 75% ethanol. It was again 
centrifuged and allowed to dry completely. 
4.2.4 For Extraction from Cancer tissue:  
           About 30 mg of frozen cancer tissue was taken and thoroughly homogenized using Lysis 
buffer. The homogenized tissue was transferred into a sterile 2 ml micro centrifuge tube 
containing 300 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-mercaptoethanol/1ml of 
Lysis Buffer). The mixture was thoroughly mixed by vortexing for 10 sec. The next steps of 
extraction were same as that followed in the previous protocol for blood RNA extraction 
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4.3 QUANTITATIVE ESTIMATION OF RNA CONCENTRATION BY 
SPECTROPHOTOMETRIC ANALYSIS: 
The concentration of the extracted total RNA from both blood and cancer tissue was quantified 
by measuring the absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 Bio 
Spectrophotometer, double beam) and calculated by using the formula as given below (Table 1) 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
 
Tissue Concentration 
(µg/ml) 
Purity 
(260/280) nm 
Purity(260/230) nm 
Normal  tissue 
(Blood) 
570.32 1.34 0.82 
Cancer 
(leukemia 
cells) 
234.67 1.03 0.65 
Table 1. Concentration and purity measurement of leukemia cells and normal cells by 
spectrophotomeric method. 
 
4.4 QUANTITATIVE ESTIMATION OF RNA CONCENTRATION BY 
DENATURING GEL   ELECTROPHORESIS: 
 
The extracted RNA from both blood and cancer tissue was run on a denaturing agarose gel and 
the quantity of RNA estimated from the band intensity. For denaturation gel (40 ml), 0.6 g 
agarose (Sigma), 28.8 ml dH2O (Sigma), 7.2 ml formaldehyde (Sigma), 4 ml 10X MOPS buffer 
were mixed properly. About 2 μl (2μg) of the total RNA was mixed with 18 μl 1X Reaction 
Buffer (2μl of 10X MOPS Buffer, 4 μl formaldehyde, 10 μl formamide (Sigma) ,2 μl 0.2 mg/ml 
Etbr (Sigma)) and incubated at 55 °C for 1 hr. It was then cooled on ice and loaded in the wells 
of the denaturing gel. 
 
4.5. FIRST STRAND cDNA SYNTHESIS: 
Total RNA (4 g) from both blood and cancer tissue were used for first strand cDNA synthesis 
by reverse transcription using RevertAid
TM
First Strand cDNA Synthesis Kit (Fermentas) in a 
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thermo cycler(Bio-Rad). The RNA were incubated with 1 l of oligo (dT)primers(100 μM, 0.2 
μg/μl) and 12 μl of nuclease-free water at 65C for 5 min.The reaction was cooled on ice to 
allow the primers to anneal to the RNA, then spin down and placed on ice again after which the 
following components were added to the reaction in order; 4l of 5X Reaction Buffer, 1 l of 
Ribolock
TM
RNase inhibitor (20 U/l), 2 l of 10mMdNTPsand 1.0 L of RevertAidTM M-
MuLV-Reverse Transcriptase (200 U/l). The reagents were gently mixed and were incubated 
for 1 h at 42C which is ambient temperature used for the practical. Heating at 70C for 5 min 
terminated the reaction and the synthesized cDNA was stored at –20 0 C for further use. 
4.6. GENE-SPECIFIC PCR FOR AMPLIFICATION OF THE DESIRED 
GENE:- 
4.6.1 SELECTION OF PRIMERS: 
A set of specific forward and reverse primers for the amplification of the desired gene under 
study was selected from a set of published papers (Patra et al., 2003; Zou et al., 2002) and primer 
selection was done. The cDNA of both the blood and cancer tissue synthesized were used as the 
template for the specific primers. The constitutively expressed housekeeping gene, β-actin was 
used as a positive control to ensure high quality. The primer sequences used for the PCR reaction 
are shown in Table showing the sequence of the forward and backward primers. 
 
 GENE                                                       PRIMERS 
 
HDAC1 
FORWARD- 5’ACGGTCTTTATAAGAAGATGATCGT-
3’ 
REVERSE- 5’CTGGGAGGCCTGGTACGGCTTGAAG-3’ 
 
β-ACTIN 
FORWARD-5‘ TCTACAATGAGCTGCGTGTG 3‘ 
REVERSE-5‘ TCTCCTTCTGCATCCTGTC 3‘ 
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4.6.2 PCR CONDITIONS: 
The PCR sample mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 
1XPCR buffer (Sigma), 0.5 μl of dNTP (0.2mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 
μl each of the forward and reverse primers (0.2 μM, Sigma) of MBD1, MBD2, MBD3, MBD4  
and 0.5 μlTaq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was added. PCR 
amplifications of MBD1, MBD2, MBD3 and MBD4 were performed in a thermal cycler by 
initial denaturation at 94° C for 1 min, followed by 30 cycles of denaturation at 94° C for 20 
secs, annealing at 57° C for 20secs, and extension at 72° C for 30 secs, followed by an final 
extension step at 72° C for 5 mins. For amplification of cDNA , the following conditions were 
followed:initial denaturation at 95° C for 5 mins, prior to 30 cycles of denaturation at 94° C for 
30 secs, annealing at 57° C for 20secs, and extension at 72° C for 45secs, followed by an final 
extension step at 72° C for 10mins. 
 
4.7 AGAROSE GEL ELECTROPHORESIS OF THE PCR PRODUCTS:- 
The generated PCR products were analyzed by electrophoresis on 1.5% agarose gel. Agarose gel 
was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 0.1% ethidium 
bromide was added to the gel. 15 μl of sample (PCR product) was loaded to each well along with 
3 μl 1 X loading dye. 5 μl of DNA marker (1 kb, Sigma). The gel was run in TAE buffer at 100 
volt for 40 minutes 
 4.8 ANALYSIS OF THE RELATIVE EXPRESSION LEVEL OF THE 
DIFFERENT GENES:  
The relative levels of expression of each gene were analyzed by taking the absorbance through 
spectrophotometric readings. The ratios of desired genes/β-actin product were subsequently 
calculated after subtraction of the background pixel intensity for each gene of interest and used 
to assess the differences in expression levels between normal and cancer tissue. 
 
                             
 
 Page 25 
 
5. RESULT AND DISCUSSION 
In study of leukemia cells HDAC-1 expression was up regulated compared with the normal cells. 
The observation was confirmed by doing experiment in lab. Experiment was performed by RNA 
isolation from both normal cells and leukemia cells and its expression was checked by running 
agarose gel. Beta actin a house keeping gene that shows same expression in all kind of cells was 
visualized for its expression. When normal cell was compared with leukemia cells HDAC-1 
expression was nil in normal cells while well bright band was observed in leukemia cells. 
RNA isolation was done by two methods one bye kit and other by manually and hence it was 
observed that RNA isolation was maximum and pure when it was extracted manually rather then 
by kit. 
                         
Fig.6 denaturing gel for normal cells                        Fig.7 denaturing gel for leukemia cells 
 
                                        
Fig.8 HDAC-1 expression in normal cells              Fig. 9 HDAC-1 expression in leukemia cells 
 
 
                                   
Fig.10 beta actin expression             Fig.11 beta actin expression in leukemia cells                                        
normal cell 
                                   
 
1            2        3 
   1                  2                3 
650 bp HDAC1 650 bp HDAC1 
1                     2                       3 
   1                       2                 3 
                1        2        3                                     1     2     3 
18S 
28S 
18S 
28S 
ladder 
Ladder
ladder 
 Page 26 
 
                       6. CONCLUSION  
 
Acetylation and Deacetylation is two regulatory and exactly opposing processes in modulation of 
histones. Acetylation is a process of addition of acetyl group to the histone while deacetylation 
removes the acetyl group from the histones. From the previous experiment it was concluded that 
HDAC1 expression was more in cancer cells and tissues and hence it was correlated with 
suppression of tumor repressor and cell cycle regulatory genes. From the experiments carried out 
in our lab it was observed that HDAC1 expression was high in leukemia cells in compared to the 
normal cells. In normal cells the expression was nil. In this context it was also observed that 
while carrying out the experiment for HDAC1 expression RNA extraction was done by two 
methods one by manually and other by the help of RNA extraction kit and it was observed that 
RNA extraction was maximum and pure when it was extracted by manually rather than by kit. 
Hence, from the above experiment it was concluded that HDAC-1 higher expression suppresses 
the tumor repressor gene and accordingly associated with some mechanisms leading to the 
cancerous stage. 
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